UPDATE : Wednesday, August 5, 2020
Shareholders in shock over HLB’s phase-3 trial setback by Jeong Sae-im 2019-06-28 10:47
‘Food and drug ministry alone can’t handle Invossa debacle’ by Jeong Sae-im 2019-06-27 12:45
Oscotech wins exception policy for continued R&D for new drugs by Jeong Sae-im 2019-06-25 14:11
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting by Jeong Sae-im 2019-06-20 14:20
294 shareholders file suit against Kolon TissueGene for damage compensation by Jeong Sae-im 2019-06-14 10:51
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe by Lee Han-soo 2019-06-13 16:10
Kolon TissueGene CEO resigns by Jeong Sae-im 2019-06-07 15:35
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’ by Lee Han-soo, KBR correspondent 2019-06-04 14:17
Kolon’s minority shareholders demand over ₩25 billion in damage by Jeong Sae-im 2019-06-03 14:53
Invossa inventor sold Kolon shares at highest value by Jeong Sae-im 2019-06-03 14:52
Until when will Kolon keep lying about Invossa? by Jeong Sae-im 2019-05-31 14:59
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug by Jeong Sae-im 2019-05-31 14:59
Announcement of Invossa license revocation was ‘procedural breach’: Kolon by Jeong Sae-im 2019-05-30 13:28
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy by Kim Yun-mi 2019-05-29 12:35
Invossa poses almost no safety threat: regulator by Lee Hye-seon 2019-05-28 16:02
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar by Lee Han-soo 2019-05-27 15:52
‘Shareholders can surely win lawsuit against Kolon’ by Jeong Sae-im 2019-05-24 19:34
‘Kolon’s extra data insufficient to explain Invossa mislabeling’ by Lee Hye-seon 2019-05-23 14:51
Prosecutors seek arrest warrant of Samsung BioLogics CEO by Lee Han-soo 2019-05-23 11:19
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients by Jeong Sae-im 2019-05-22 11:59
Back to Top